Filing Flows › Companies › Boston Scientific › Timeline
Boston Scientific stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions−56.9% to $42.75
Boston Scientific (BSX) stock fell 57% over the last 252 sessions, to $42.75. On the way it reported 4 quarters, its insiders filed 5 open-market trades, and the company filed 9 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Oct 28, 2026 | Earnings | Earnings: beat the EPS estimate by 0.9% | −6.0% (−6.3% vs SPY) | −3.5% (−1.5% vs SPY) | — |
| Oct 7, 2026 | 8-K | Directors and officers: departures, appointments, pay | −1.5% (−1.2% vs SPY) | +2.6% (+2.7% vs SPY) | +8.2% (+9.8% vs SPY) |
| Sep 23, 2026 | 8-K | Directors and officers: departures, appointments, pay | −0.7% (+0.1% vs SPY) | −2.3% (−1.2% vs SPY) | −0.9% (−0.9% vs SPY) |
| Sep 8, 2026 | 8-K | Material cybersecurity incident | −6.1% (−5.5% vs SPY) | −5.9% (−4.7% vs SPY) | −12.5% (−13.9% vs SPY) |
| Aug 25, 2026 | Insider buy | Morano Susan E bought $100K | +1.7% (+1.4% vs SPY) | −1.5% (−1.9% vs SPY) | −9.4% (−10.2% vs SPY) |
| Aug 5, 2026 | Insider buy | Habiger David C bought $100K | −2.8% (−2.6% vs SPY) | +4.2% (+4.3% vs SPY) | −1.5% (−0.7% vs SPY) |
| Aug 3, 2026 | Insider buy | Mahoney Michael F bought $9.0M | +3.6% (+2.2% vs SPY) | +5.4% (+1.9% vs SPY) | +3.3% (+0.7% vs SPY) |
| Aug 3, 2026 | Insider buy | Habiger David C bought $50K | +3.6% (+2.2% vs SPY) | +5.4% (+1.9% vs SPY) | +3.3% (+0.7% vs SPY) |
| Jul 31, 2026 | Insider buy | Ludwig Edward J bought $227K | +1.6% (+0.8% vs SPY) | +6.9% (+3.4% vs SPY) | +1.8% (−1.9% vs SPY) |
| Jul 29, 2026 | Earnings | Earnings: beat the EPS estimate by 3.9% | 0.0% (+1.5% vs SPY) | +6.4% (+2.3% vs SPY) | +4.5% (+1.1% vs SPY) |
| Jul 27, 2026 | 8-K | Exit or disposal costs | +1.2% (+1.0% vs SPY) | +6.2% (+3.7% vs SPY) | +9.1% (+5.6% vs SPY) |
| Apr 22, 2026 | Earnings | Earnings: beat the EPS estimate by 1.6% | +8.6% (+7.6% vs SPY) | −1.8% (−2.9% vs SPY) | −4.9% (−10.0% vs SPY) |
| Feb 26, 2026 | 8-K | Material definitive agreement | +1.4% (+1.9% vs SPY) | −3.7% (−2.6% vs SPY) | −9.1% (−1.0% vs SPY) |
| Feb 23, 2026 | 8-K | Directors and officers: departures, appointments, pay | +1.0% (+0.3% vs SPY) | +2.5% (+1.9% vs SPY) | −8.7% (−4.6% vs SPY) |
| Feb 5, 2026 | 8-K | Directors and officers: departures, appointments, pay | −1.8% (−3.7% vs SPY) | −4.6% (−5.2% vs SPY) | −7.7% (−7.8% vs SPY) |
| Feb 4, 2026 | Earnings | Earnings: beat the EPS estimate by 2.4% | −19.3% (−18.9% vs SPY) | −21.0% (−21.4% vs SPY) | −22.7% (−21.5% vs SPY) |
| Jan 15, 2026 | 8-K | Material definitive agreement | −2.2% (−2.1% vs SPY) | +2.7% (+3.2% vs SPY) | −16.5% (−15.2% vs SPY) |
| Nov 19, 2025 | 8-K | Directors and officers: departures, appointments, pay | −0.4% (+1.1% vs SPY) | +4.0% (+1.4% vs SPY) | −1.5% (−4.4% vs SPY) |
Insiders’ record here
In the year on the chart, Boston Scientific's insiders reported 5 open-market buys ($9.5M) and 0 sales ($0). Of the 4 old enough to score, 0 were followed by the stock doing what the trade implied over the next 63 sessions (beating SPY after a buy, lagging it after a sale); the median excess return after a buy was −11.6% and after a sale —.
Across the whole universe (19,782 scored trades), insider buys beat the market 46% of the time and sales were followed by a lagging stock 61% of the time; buys of $1M or more 39%. Every pattern →
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
| 1.01 Material definitive agreement | 23,525 | 0.0% | 51% | +1.0% | ±1.4% |
| 1.02 Termination of a material agreement | 2,368 | 0.0% | 51% | +1.1% | ±1.5% |
| 2.03 New debt or off-balance-sheet obligation | 13,268 | 0.0% | 50% | +1.2% | ±1.3% |
| 2.05 Exit or disposal costs | 954 | −0.2% | 47% | +0.5% | ±2.4% |
| 1.05 Material cybersecurity incident | 42 | −0.6% | 33% | −0.2% | ±1.6% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → Boston Scientific: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.